Catalyst Wire Dossier Catalyst Wire Dossier

Crizanlizumab (Adakveo)

crizanlizumab · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Crizanlizumab (Adakveo), covering 2025-01-08 to 2025-01-08. Get the full timeline:

Most recent: Clinical Trial Update: An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients [Phase 4]

See pricing